281 related articles for article (PubMed ID: 26189084)
1. Intrathecal 2-hydroxypropyl-beta-cyclodextrin in a single patient with Niemann-Pick C1.
Maarup TJ; Chen AH; Porter FD; Farhat NY; Ory DS; Sidhu R; Jiang X; Dickson PI
Mol Genet Metab; 2015; 116(1-2):75-9. PubMed ID: 26189084
[TBL] [Abstract][Full Text] [Related]
2. Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial.
Ory DS; Ottinger EA; Farhat NY; King KA; Jiang X; Weissfeld L; Berry-Kravis E; Davidson CD; Bianconi S; Keener LA; Rao R; Soldatos A; Sidhu R; Walters KA; Xu X; Thurm A; Solomon B; Pavan WJ; Machielse BN; Kao M; Silber SA; McKew JC; Brewer CC; Vite CH; Walkley SU; Austin CP; Porter FD
Lancet; 2017 Oct; 390(10104):1758-1768. PubMed ID: 28803710
[TBL] [Abstract][Full Text] [Related]
3. Differential Effects of 2-Hydroxypropyl-Cyclodextrins on Lipid Accumulation in
Hoque S; Kondo Y; Sakata N; Yamada Y; Fukaura M; Higashi T; Motoyama K; Arima H; Higaki K; Hayashi A; Komiya T; Ishitsuka Y; Irie T
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019132
[TBL] [Abstract][Full Text] [Related]
4. Early experience with compassionate use of 2 hydroxypropyl-beta-cyclodextrin for Niemann-Pick type C disease: review of initial published cases.
Megías-Vericat JE; García-Robles A; Company-Albir MJ; Fernández-Megía MJ; Pérez-Miralles FC; López-Briz E; Casanova B; Poveda JL
Neurol Sci; 2017 May; 38(5):727-743. PubMed ID: 28155026
[TBL] [Abstract][Full Text] [Related]
5. Cholesterol homeostatic responses provide biomarkers for monitoring treatment for the neurodegenerative disease Niemann-Pick C1 (NPC1).
Tortelli B; Fujiwara H; Bagel JH; Zhang J; Sidhu R; Jiang X; Yanjanin NM; Shankar RK; Carillo-Carasco N; Heiss J; Ottinger E; Porter FD; Schaffer JE; Vite CH; Ory DS
Hum Mol Genet; 2014 Nov; 23(22):6022-33. PubMed ID: 24964810
[TBL] [Abstract][Full Text] [Related]
6. In Vitro and In Vivo Evaluation of 6-O-α-Maltosyl-β-Cyclodextrin as a Potential Therapeutic Agent Against Niemann-Pick Disease Type C.
Yasmin N; Ishitsuka Y; Fukaura M; Yamada Y; Nakahara S; Ishii A; Kondo Y; Takeo T; Nakagata N; Motoyama K; Higashi T; Okada Y; Nishikawa J; Ichikawa A; Iohara D; Hirayama F; Higaki K; Ohno K; Matsuo M; Irie T
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845767
[TBL] [Abstract][Full Text] [Related]
7. Differential mode of cholesterol inclusion with 2-hydroxypropyl-cyclodextrins increases safety margin in treatment of Niemann-Pick disease type C.
Yamada Y; Ishitsuka Y; Kondo Y; Nakahara S; Nishiyama A; Takeo T; Nakagata N; Motoyama K; Higashi T; Arima H; Kamei S; Shuto T; Kai H; Hayashino Y; Sugita M; Kikuchi T; Hirata F; Miwa T; Takeda H; Orita Y; Seki T; Ohta T; Kurauchi Y; Katsuki H; Matsuo M; Higaki K; Ohno K; Matsumoto S; Era T; Irie T
Br J Pharmacol; 2021 Jul; 178(13):2727-2746. PubMed ID: 33782944
[TBL] [Abstract][Full Text] [Related]
8. Long-term administration of intravenous Trappsol® Cyclo™ (HP-β-CD) results in clinical benefits and stabilization or slowing of disease progression in patients with Niemann-Pick disease type C1: Results of an international 48-week Phase I/II trial.
Sharma R; Hastings C; Staretz-Chacham O; Raiman J; Paucar M; Spiegel R; Murray B; Hurst B; Liu B; Kjems L; Hrynkow S
Mol Genet Metab Rep; 2023 Sep; 36():100988. PubMed ID: 37670901
[TBL] [Abstract][Full Text] [Related]
9. Intracerebroventricular Treatment with 2-Hydroxypropyl-β-Cyclodextrin Decreased Cerebellar and Hepatic Glycoprotein Nonmetastatic Melanoma Protein B (GPNMB) Expression in Niemann-Pick Disease Type C Model Mice.
Fukaura M; Ishitsuka Y; Shirakawa S; Ushihama N; Yamada Y; Kondo Y; Takeo T; Nakagata N; Motoyama K; Higashi T; Arima H; Kurauchi Y; Seki T; Katsuki H; Higaki K; Matsuo M; Irie T
Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33466390
[TBL] [Abstract][Full Text] [Related]
10. Fine-tuned cholesterol solubilizer, mono-6-O-α-D-maltosyl-γ-cyclodextrin, ameliorates experimental Niemann-Pick disease type C without hearing loss.
Yamada Y; Miwa T; Nakashima M; Shirakawa A; Ishii A; Namba N; Kondo Y; Takeo T; Nakagata N; Motoyama K; Higashi T; Arima H; Kurauchi Y; Seki T; Katsuki H; Okada Y; Ichikawa A; Higaki K; Hayashi K; Minami K; Yoshikawa N; Ikeda R; Ishikawa Y; Kajii T; Tachii K; Takeda H; Orita Y; Matsuo M; Irie T; Ishitsuka Y
Biomed Pharmacother; 2022 Nov; 155():113698. PubMed ID: 36116252
[TBL] [Abstract][Full Text] [Related]
11. Collaborative development of 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick type C1 disease.
Ottinger EA; Kao ML; Carrillo-Carrasco N; Yanjanin N; Shankar RK; Janssen M; Brewster M; Scott I; Xu X; Cradock J; Terse P; Dehdashti SJ; Marugan J; Zheng W; Portilla L; Hubbs A; Pavan WJ; Heiss J; Vite CH; Walkley SU; Ory DS; Silber SA; Porter FD; Austin CP; McKew JC
Curr Top Med Chem; 2014; 14(3):330-9. PubMed ID: 24283970
[TBL] [Abstract][Full Text] [Related]
12. Intravenous 2-hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral tissues in adult subjects with Niemann-Pick Disease Type C1: Results of a phase 1 trial.
Hastings C; Liu B; Hurst B; Cox GF; Hrynkow S
Mol Genet Metab; 2022 Dec; 137(4):309-319. PubMed ID: 36279795
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Treatment of Niemann-Pick Type C1 Disease With Intrathecal 2-Hydroxypropyl-β-Cyclodextrin.
Berry-Kravis E; Chin J; Hoffmann A; Winston A; Stoner R; LaGorio L; Friedmann K; Hernandez M; Ory DS; Porter FD; O'Keefe JA
Pediatr Neurol; 2018 Mar; 80():24-34. PubMed ID: 29429782
[TBL] [Abstract][Full Text] [Related]
14. In vitro evaluation of 2-hydroxyalkylated β-cyclodextrins as potential therapeutic agents for Niemann-Pick Type C disease.
Kondo Y; Tokumaru H; Ishitsuka Y; Matsumoto T; Taguchi M; Motoyama K; Higashi T; Arima H; Matsuo M; Higaki K; Ohno K; Irie T
Mol Genet Metab; 2016 Jul; 118(3):214-219. PubMed ID: 27184436
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and distribution of 2-hydroxypropyl-β-cyclodextrin following a single intrathecal dose to cats.
Kao ML; Stellar S; Solon E; Lordi A; Kasica N; Swain G; Bagel JH; Gurda BL; Vite CH
J Inherit Metab Dis; 2020 May; 43(3):618-634. PubMed ID: 31707730
[TBL] [Abstract][Full Text] [Related]
16. Use of 2 hydroxypropyl-beta-cyclodextrin therapy in two adult Niemann Pick Type C patients.
García-Robles AA; Company-Albir MJ; Megías-Vericat JE; Fernández-Megía MJ; Pérez-Miralles FC; López-Briz E; Alcalá-Vicente C; Galeano I; Casanova B; Poveda JL
J Neurol Sci; 2016 Jul; 366():65-67. PubMed ID: 27288778
[No Abstract] [Full Text] [Related]
17. Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-Pick type C1 disease.
Vite CH; Bagel JH; Swain GP; Prociuk M; Sikora TU; Stein VM; O'Donnell P; Ruane T; Ward S; Crooks A; Li S; Mauldin E; Stellar S; De Meulder M; Kao ML; Ory DS; Davidson C; Vanier MT; Walkley SU
Sci Transl Med; 2015 Feb; 7(276):276ra26. PubMed ID: 25717099
[TBL] [Abstract][Full Text] [Related]
18. Hydroxypropyl-beta and -gamma cyclodextrins rescue cholesterol accumulation in Niemann-Pick C1 mutant cell via lysosome-associated membrane protein 1.
Singhal A; Szente L; Hildreth JEK; Song B
Cell Death Dis; 2018 Oct; 9(10):1019. PubMed ID: 30282967
[TBL] [Abstract][Full Text] [Related]
19. 2-hydroxypropyl-beta-cyclodextrin raises hearing threshold in normal cats and in cats with Niemann-Pick type C disease.
Ward S; O'Donnell P; Fernandez S; Vite CH
Pediatr Res; 2010 Jul; 68(1):52-6. PubMed ID: 20357695
[TBL] [Abstract][Full Text] [Related]
20. Anesthetic management of pediatric patients with Niemann-Pick disease type C for intrathecal 2-hydroxypropyl-β-cyclodextrin injection.
Ulloa ML; Froyshteter AB; Kret LN; Chang DP; Sarah GE; McCarthy RJ; Barnes SD; Berry-Kravis EM
Paediatr Anaesth; 2020 Jul; 30(7):766-772. PubMed ID: 32349180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
